SlideServe
Menu
Préférences
© SlideServe · v2026

Improving our understanding of Aspergillus fumigatus

iria avatar
15 diapositives · 640 Views · Jul 13, 2014

Improving our understanding of Aspergillus fumigatus. Project Overview. Aspergillus fumigatus. RNA- Seq. WGS. SNP calling. Statistical analysis. Network analysis. Why sequence Aspergillus fumigatus ? . Allergic aspergillosis – associated with asthma Invasive aspergillosis

Improving our understanding of Aspergillus fumigatus - slide 1
01 / 15Improving our understanding of Aspergillus fumigatus
1 / 17

Télécharger la présentation

Improving our understanding of Aspergillus fumigatus
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation
  1. Improving our understanding of Aspergillusfumigatus

  2. Project Overview Aspergillusfumigatus • RNA-Seq • WGS • SNP calling • Statistical analysis • Network analysis

  3. Why sequence Aspergillus fumigatus? • Allergic aspergillosis – associated with asthma • Invasive aspergillosis • > 40% hospital acquired ? • Very high mortality rate (50–90%) in treated patients • No effective drugs, vaccines or diagnostics • Emerging drug resistance: 10%-50% Bueid et al., 2010 Invasive aspergillosis

  4. Two additional reference genomes Mitochodrial genetic diversity • AF10 and AF210 – chosen because they are different from Af293 and Af1163 • Unique MLST types • Af10: Clinical isolate from immunosuppressed patient in LA; fully susceptible to azoles and amphothericin B • Af210: Nosocomial infection in Manchester; MLST identical to ICU environmental strain and 5 other clinical samples • Sequencing completed; annotation pending • Mitochondria compared for 11 Aspergillusand Penicilliumgenomes Joardar, submitted

  5. Novel drug resistance mechanisms:SNP calling, clustering, and association *sequential resistant isolates TBS SNP density along the 8 Afu293 chromosomes show a subtelomere bias SNP/10Kb

  6. >50 loci show extreme allelic variability between strains • Greater than 15 SNPs/Kb • Several involved in vegetative incompatibility HET locus AFUB_017990 GBrowse2

  7. Significant variability is also present in drug resistance genes • Cyp51A: 10-12 SNPs • Mdr1/AtrD ABC transporter: 2-8 SNPs cyp51A asn2 GBrowse2

  8. Annotation improvement with RNAseq 630 updates so far • Use sequence reads to validate and/or modify existing gene models • Update categories • Gene extension • Gene mergers • UTRs • Alternative Isoforms • Novel genes • Exon boundary adjustments • Validation of hypotheticals

  9. RNA-Seq reveals alternative isoforms in a transcription factor linked to hypoxia AFUB_018340 GBrowse2

  10. RNA-Seq identifies novel genes Novel genes

  11. RNA-Seqexpression profiling of host-pathogen interactions • Fungusexposed vs. non-exposed to NK cells • 171 genes • 63 genes • Human NK cells exposed to fungus • 503 genes • 518 genes • => Pathway enrichment and network analysis • Key drivers of the transcriptional changes • Targets for immuno-modulation therapy

  12. Outbreak Investigation • Current methodology depends on analysis of short tandem repeats at 6 loci in the genome • However, there are no high-confidence global SNP markers for outbreak investigation • Sequenced “clonal” strains from two different outbreaks to understand variability • Identify novel SNPs to be used as markers • Technology is complementary to currently used typing schemes

  13. Future directions • Integration of omics data for drug resistant isolates • => Drug resistance and diagnostic arrays • Additional genotyping markers • Ribosomal monomers • Mitochondrial genomes • HET genes • => Geographic variation and disease phenotypes • RNA-Seqsoftware evaluation tool • Sequencing of a highly virulent species A. tanneri • Development of a system for genetic analysis of A. fumigatus • Sequencing of “supermaters” • Testing drug resistance SNPs

  14. Acknowledgements • J. Craig Venter Institute • Informatics • Natalie FedorovaAbrams • Suman Pakala • Vinita Joardar • NikhatZafar • Suchitra Pakala • PratapVenepally • VenkiMoktali • Culture & sample prep • Stephanie Maunoud • Yan Yu • Tatiana Slepushkina • Ashlee Dravis • IFX, IT, Sequencing Core • GSCID directors at JCVI • Bill Nierman • Karen Nelson • Funding: NIAID/NIH • Outside collaborators • U. of Manchester: David Denning • NIAID/NIH: June Kwon-Chung • CDC: Arun Balajee • U. of Montana: Robb Cramer • U. of Georgia: Michelle Momany • U. of Tuebingen: JuergenLoeffler • U. of Wisconsin: Nancy Keller

  15. Questions